Roche has entered into an agreement with Evotec to fund the Phase II clinical development of a selective N-methyl-D-aspartate (NMDA) receptor antagonist, EVT 101, for patients with treatment ...

Researchers at Bexson Biomedical Inc. and Saint Joseph’s University have synthesized NMDA receptor antagonists reported to be useful for the treatment of neurological and psychiatric disorders.

It is the first and only oral NMDA receptor antagonist to be approved for this use, and the first oral therapy with a new mechanism of action in around 60 years, said Axsome. NMDA antagonist ...

NMDA (N-methyl-D-aspartate) receptors (NMDARs) are the most important known trigger for long-term synaptic plasticity. They also show considerable mobility within the membrane and between ...

In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...

To see if a treatment that targets NMDA receptors might be effective in fragile X, they tried an experimental drug called ...

A new study shows that when energy is depleted—such as during a stroke—neurons begin releasing glutamate in abnormal, self-amplifying bursts that can damage nerve cells.

Tests for paraneoplastic and voltage-gated potassium channel antibodies were negative, but antibodies to N-methyl-D-aspartate receptors (NMDARs) were identified in serum and CSF (Figure 2).

NO SIGNALING:© 2003 Annual ReviewsAll images redrawn from D. Boehning, S.H. Snyder, Ann Rev Neurosci, 26:105–31, 2003.Neuronal nitric oxide synthase (nNOS) is localized to NMDA receptors by the ...

Meanwhile, Johnson & Jonson's orexin 2 antagonist seltorexant, Intra-Cellular Therapies' serotonin 5-HT2a antagonist Caplyta (lumateperone), and Relmada Therapeutic' NMDA drug dextromethadone (REL ...

Neumora Therapeutics, Inc.’s NMRA share price has surged by 10.34%, which has investors questioning if this is right time to ...